Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DCC-3009 + Rabeprazole |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DCC-3009 | DCC3009|DCC 3009 | KIT Inhibitor 57 | DCC-3009 is a KIT inhibitor with activity against exon 9 and 11 mutations, as well as mutations in exons 13, 14, 17, and 18, potentially resulting in decreased tumor growth (Cancer Res (2023) 83 (7_Supplement): 4033). | |
| Rabeprazole | AcipHex | Irsogladine Maleate |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06630234 | Phase Ib/II | DCC-3009 DCC-3009 + Rabeprazole | A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) | Recruiting | USA | 0 |